相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma How Different are these From Conventional Treatment Responses?
Gregory K. Pennock et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
Surgical Management of Melanoma Lung Metastasis: An Analysis of Survival Outcomes in 292 Consecutive Patients
Terence C. Chua et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I)
J. Harrison Howard et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto et al.
CLINICAL CANCER RESEARCH (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
Alexander M. M. Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2012)
Ipilimumab in the treatment of melanoma
Van A. Trinh et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline
Sandra L. Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
IFN-α in the Treatment of Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF IMMUNOLOGY (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2: Tumor and Immunological Responses
Steven K. Seung et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines
Thejaswi K. Poonacha et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Does Metastasectomy Improve Survival in Patients With Stage IV Melanoma? A Cancer Registry Analysis of Outcomes
Nabil Wasif et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
Johan Hansson et al.
LANCET ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Claus Garbe et al.
ONCOLOGIST (2011)
Survival after Pulmonary Metastasectomy in Patients with Malignant Melanoma
C. Schuhan et al.
THORACIC AND CARDIOVASCULAR SURGEON (2011)
Predicting Survival Outcome of Localized Melanoma: An Electronic Prediction Tool Based on the AJCC Melanoma Database
Seng-jaw Soong et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
A High Molecular Weight Melanoma-Associated Antigen-Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
William R. Burns et al.
CANCER RESEARCH (2010)
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
Howard L. Kaufman et al.
FUTURE ONCOLOGY (2010)
Efficacy of Low-Dose Interferon α2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of ≥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
Simone Mocellin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
Andrew Bottomley et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Randomized Multicenter Adjuvant Dermatologic Cooperative Oncology Group Trial of Low-Dose Interferon Alfa-2b With or Without a Modified High-Dose Interferon Alfa-2b Induction Phase in Patients With Lymph Node-Negative Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion
Axel Hauschild et al.
CANCER (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
Interferon-α influences tryptophan metabolism without inducing psychiatric side effects
Marjolein Bannink et al.
NEUROPSYCHOBIOLOGY (2007)
Prognostic significance of autoimmunity during treatment of melanoma with interferon
H Gogas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2
KA Chianese-Bullock et al.
JOURNAL OF IMMUNOTHERAPY (2005)
A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma
JM Kirkwood et al.
CLINICAL CANCER RESEARCH (2004)
Interferon alpha as adjuvant postsurgical treatment of melanoma: A meta-analysis
D Pirard et al.
DERMATOLOGY (2004)
Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-α
M Schaefer et al.
BRAIN BEHAVIOR AND IMMUNITY (2004)
Adjuvant interferon in high-risk melanoma: The AIM HIGH study-United Kingdom Coordinating Committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma
BW Hancock et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis
A Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients
AR Van Gool et al.
PSYCHIATRY RESEARCH (2003)
Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy
L Capuron et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer
PG Fraenkel et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Guidelines for the safe administration of high-dose interleukin-2
DJ Schwartzentruber
JOURNAL OF IMMUNOTHERAPY (2001)
Paroxetine for the prevention of depression induced by high-dose interferon alfa
DL Musselman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
